BOEHRINGER INGELHEIM INTERNATIONALGMBH

Their core work

Boehringer Ingelheim is one of the world's largest research-driven pharmaceutical companies, headquartered in Ingelheim, Germany. Within H2020, they contribute deep drug development expertise — particularly in translational safety, biomarker discovery, and clinical trial innovation — across large public-private partnerships. Their participation spans the full drug lifecycle: from preclinical toxicology and safety assessment through to patient-reported outcomes and real-world evidence generation. They are a major industry contributor to the Innovative Medicines Initiative (IMI), providing proprietary data, compound libraries, and clinical expertise to pre-competitive research consortia.

What they specialise in

How they've shifted over time

In the early period (2015–2018), Boehringer Ingelheim focused heavily on translational safety, preclinical data quality, and regulatory pathways — the foundational infrastructure of drug development. Projects like eTRANSAFE, TransQST, EQIPD, and ADAPT-SMART reflect a company investing in making drug safety assessment more reliable and data-driven. From 2019 onward, their focus shifted markedly toward AI-driven approaches (MELLODDY, BIGPICTURE), federated data sharing, deep molecular phenotyping (BIOMAP), and decentralized clinical trials (Trials@Home) — signaling a digital transformation of their R&D pipeline.

Boehringer Ingelheim is rapidly building capabilities in privacy-preserving AI and federated data analysis, positioning itself for a future where pharma R&D relies on distributed, multi-site machine learning rather than centralized data pools.

How they like to work

Boehringer Ingelheim exclusively participates as a consortium partner — never as coordinator in H2020 — which is typical for large pharma in IMI projects where academic or SME partners formally lead while industry provides data, compounds, and co-funding. With 399 unique partners across 31 countries, they operate as a highly connected hub in European health research. Their consistent presence across 23 projects over six years suggests they are a reliable, long-term consortium member rather than a one-off participant.

With 399 unique consortium partners across 31 countries, Boehringer Ingelheim has one of the densest collaboration networks in H2020 health research. Their reach is pan-European with strong ties to academic medical centers, other pharma companies, and data infrastructure providers across the EU.

What sets them apart

Boehringer Ingelheim brings something rare to consortia: a top-20 global pharma company willing to share proprietary preclinical and clinical data in pre-competitive settings. Their participation in both safety-focused projects (eTRANSAFE, TransQST) and data-sharing initiatives (EHDEN, FAIRplus, MELLODDY) means they bridge the gap between industry data vaults and open science. For consortium builders, they offer credibility, real-world drug development data, and the capacity to translate research outputs into actual pharmaceutical R&D pipelines.

Highlights from their portfolio

• MELLODDY
  Pioneered federated machine learning across 10 pharma companies — each trained shared models on proprietary drug data without exposing it, a first-of-its-kind approach in pharmaceutical AI.
• eTRANSAFE
  One of the largest IMI projects on drug safety, integrating preclinical and clinical safety data across the industry to build predictive toxicology tools.
• BIOMAP
  Ambitious multi-omics biomarker project for inflammatory skin diseases, combining single-cell analysis, deep phenotyping, and disease mapping at unprecedented scale.